Halozyme Therapeutics (HALO) Q2 2024 earnings summary

Executive summary

• Achieved strong Q2 2024 results with total revenue of $231.4 million, up 5% year-over-year, driven by robust royalty growth, proprietary product sales, and key product approvals and IP portfolio expansion.

• Net income reached $93.2 million, adjusted EBITDA was $137 million, and non-GAAP diluted EPS increased 23% to $0.91; GAAP diluted EPS was $0.72.

• Completed $250 million accelerated share repurchase in Q2, finalizing a $750 million program; a new $750 million repurchase program was authorized.

• Multiple regulatory approvals and submissions for partner products, including new indications and geographies for DARZALEX FASPRO, VYVGART Hytrulo, and Ocrevus SC.

• Maintained increased 2024 guidance following a new EU patent for ENHANZE rHuPH20, supporting long-term royalty streams and extending royalty rates for key products to 2029.

Financial highlights

• Q2 2024 revenue was $231.4 million, up 5% year-over-year; royalty revenue reached $124.9 million, a 12% increase year-over-year.

• Net income for Q2 2024 was $93.2 million, up 25% year-over-year; operating income was $117.2 million, up 24% year-over-year.

• Adjusted EBITDA rose 19% to $137 million; non-GAAP diluted EPS increased 23% to $0.91.

• Cash, cash equivalents, and marketable securities totaled $529 million as of June 30, 2024.

• Cost of sales and SG&A expenses decreased year-over-year, supporting margin expansion.

Outlook and guidance

• 2024 guidance: total revenue of $935 million to $1.015 billion, royalty revenue of $520–$555 million, adjusted EBITDA of $555–$615 million, and non-GAAP diluted EPS of $3.65–$4.05.

• Royalty revenue and EPS growth expected to outpace top-line growth, with full-year royalty growth of 16%–24%.

• Projecting $1 billion in royalty revenue by 2027, driven by Wave 2 and Wave 3 product launches.

• Adjusted EBITDA margin guidance increased to 59–61% for 2024.

• Current liquidity expected to fund operations for at least the next twelve months.